DK1363676T3 - Fremgangsmåde til forögelse af administration af en terapeutisk nukleinsyre - Google Patents

Fremgangsmåde til forögelse af administration af en terapeutisk nukleinsyre

Info

Publication number
DK1363676T3
DK1363676T3 DK02704215T DK02704215T DK1363676T3 DK 1363676 T3 DK1363676 T3 DK 1363676T3 DK 02704215 T DK02704215 T DK 02704215T DK 02704215 T DK02704215 T DK 02704215T DK 1363676 T3 DK1363676 T3 DK 1363676T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
therapeutic nucleic
enhancing
administration
host
Prior art date
Application number
DK02704215T
Other languages
English (en)
Inventor
James G Barsoum
Michael Parr
Stephen E Fawell
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1363676T3 publication Critical patent/DK1363676T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
DK02704215T 2001-01-22 2002-01-22 Fremgangsmåde til forögelse af administration af en terapeutisk nukleinsyre DK1363676T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26341601P 2001-01-22 2001-01-22
PCT/US2002/001797 WO2002056918A2 (en) 2001-01-22 2002-01-22 Method of enhancing delivery of a therapeutic nucleic acid

Publications (1)

Publication Number Publication Date
DK1363676T3 true DK1363676T3 (da) 2007-07-23

Family

ID=23001688

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02704215T DK1363676T3 (da) 2001-01-22 2002-01-22 Fremgangsmåde til forögelse af administration af en terapeutisk nukleinsyre

Country Status (13)

Country Link
US (1) US7534424B2 (da)
EP (1) EP1363676B1 (da)
JP (1) JP2005502585A (da)
AT (1) ATE357935T1 (da)
AU (1) AU2002237910B2 (da)
CA (1) CA2435443A1 (da)
CY (1) CY1106676T1 (da)
DE (1) DE60219142T2 (da)
DK (1) DK1363676T3 (da)
ES (1) ES2283524T3 (da)
NZ (1) NZ527645A (da)
PT (1) PT1363676E (da)
WO (1) WO2002056918A2 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696423B1 (en) * 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
JP4736413B2 (ja) * 2004-12-14 2011-07-27 富士ゼロックス株式会社 生体分子保持物及び生体分子の保存方法
JPWO2011074564A1 (ja) * 2009-12-15 2013-04-25 タカラバイオ株式会社 アデノウイルスベクターの製造方法
US20140141065A1 (en) * 2012-11-19 2014-05-22 Discovery Genomics, Inc. Method to achieve extended expression of dna infused into liver

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
DE19525900C1 (de) * 1995-07-15 1996-12-12 Max Planck Gesellschaft Leberspezifischer Adenovirus-Expressionsvektor
US6696423B1 (en) * 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
CZ297314B6 (cs) * 1997-08-29 2006-11-15 Biogen Idec Ma Inc. Farmaceutický prípravek pro lécení rakoviny obsahující virový vektor s genem kódujícím protein interferon-beta
US20010031741A1 (en) * 2000-02-17 2001-10-18 Robin Ziegler Methods for treatment of lysosomal storage diseases

Also Published As

Publication number Publication date
US20040086486A1 (en) 2004-05-06
WO2002056918A2 (en) 2002-07-25
US7534424B2 (en) 2009-05-19
ES2283524T3 (es) 2007-11-01
DE60219142T2 (de) 2007-12-13
JP2005502585A (ja) 2005-01-27
EP1363676A2 (en) 2003-11-26
CA2435443A1 (en) 2002-07-25
EP1363676B1 (en) 2007-03-28
WO2002056918B1 (en) 2004-04-08
NZ527645A (en) 2008-10-31
PT1363676E (pt) 2007-06-22
AU2002237910C1 (en) 2002-07-30
CY1106676T1 (el) 2012-05-23
WO2002056918A3 (en) 2002-11-14
DE60219142D1 (de) 2007-05-10
AU2002237910B2 (en) 2007-01-25
ATE357935T1 (de) 2007-04-15

Similar Documents

Publication Publication Date Title
PL371736A1 (en) Method for administering glp-1 molecules
WO2004084950A3 (en) Cell targeting methods and compositions
NO20065860L (no) Stabiliserte flytende interferonformuleringer
LU91680I2 (fr) "rilonacept et ses dérivés pharmaceutiquement acceptables (ARCALYSR)"
HUP0401534A2 (hu) Módosított humán IX. faktor
HK1065562A1 (en) Methods and compositions for rnai mediated inhibition of gene expression in mammals
WO2002006316A3 (en) Alpha-msh related compounds and methods of use
DE50211110D1 (de) INJEKTIONSGERÄT FÜR mRNA APPLIKATION
ATE510011T1 (de) Neue pilzproteine und diese codierende nukleinsäuren
GB2398220A (en) Automated foot bath apparatus and method
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
CY1110547T1 (el) Συμπυκνωμενα πρωτεϊνικα σκευασματα μειωμενου ιξωδους
DK1163349T3 (da) Medicinske præparater til behandling af alfa-galactosidase A-mangel
WO2003093469A3 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
WO2003030821A3 (en) Albumin fusion proteins
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DE60036537D1 (de) Zusammensetzungen zur gentherapie von diabetes
DK1290011T3 (da) Melphalan-derivater og deres anvendelse som cancer-kemoterapeutiske lægemidler
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
MX2009003636A (es) Nuevos peptidos para tratar y prevenir trastornos relacionados al sistema inmunitario, incluyendo el tratamiento y prevencion de la infeccion por modulacion de la inmunidad innata.
NO20073914L (no) Biologisk aktive peptider
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
DK1363676T3 (da) Fremgangsmåde til forögelse af administration af en terapeutisk nukleinsyre
WO2005042566A3 (en) Antiangiogenicpeptides for treating or preventing endometriosis
WO2003106640A3 (en) CELL TARGETING METHODS AND COMPOSITIONS